Systematic pan-cancer analysis identified NCOA4 as an immunological and prognostic biomarker and validated in lung adenocarcinoma
Abstract Background: Cancer immunotherapy has revolutionized treatment, yet predicting patient responses remains challenging. The potential of nuclear receptor coactivator 4…